Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 15 versus RENOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 15 versus RENOTEC.
CAPOZIDE 50/15 vs RENOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPOZIDE 50/15 combines captopril (angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- cotransporter in distal convoluted tubules.
Renotec is a direct renin inhibitor that binds to the active site of renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and lowering blood pressure.
Oral, 1 tablet (captopril 50 mg / hydrochlorothiazide 15 mg) once daily. May increase to 2 tablets daily in divided doses if needed.
Enalapril 5-40 mg orally once or twice daily; initial dose 5 mg once daily, titrate based on response.
None Documented
None Documented
Captopril: terminal half-life ~2 hours (in patients with normal renal function; prolonged in renal impairment to 21-36 hours). Hydrochlorothiazide: half-life 6-15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: dosing interval affected by renal function.
Terminal elimination half-life is 12-15 hours; clinical context: supports once-daily dosing; half-life may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Captopril: renal excretion of unchanged drug and metabolites, primarily in urine (60-75%), with ~20% as unchanged captopril; small amount in feces (5-10%). Hydrochlorothiazide: renal excretion (95% unchanged), <5% via biliary/fecal.
Approximately 70% of the dose is excreted in urine as unchanged drug, and 20-30% via feces as metabolites; less than 5% is excreted unchanged in feces.
Category C
Category C
ACE Inhibitor and Diuretic Combination
ACE Inhibitor